![Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study - The Lancet Haematology Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/70db414d-1c3c-4174-8f49-00d0b88cd152/gr3.jpg)
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study - The Lancet Haematology
![PDF) Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism PDF) Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism](https://i1.rgstatic.net/publication/315465186_Developing_and_evaluating_rare_disease_educational_materials_co-created_by_expert_clinicians_and_patients_the_paradigm_of_congenital_hypogonadotropic_hypogonadism/links/58d36d5ea6fdccd24d43c887/largepreview.png)
PDF) Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism
![https://www.dw.com/ru/erich-maria-remarque-sudba-knigi-zhenshhiny/a-500523 2020-09-25T07:20:41.046Z weekly 0.5 https://www.dw.com/ru/jablochnoe-vino-v-gessene/a-2106445 2020-08-10T09:27:26.178Z weekly 0.5 https://www.dw.com/ru/9-nojabrja ... https://www.dw.com/ru/erich-maria-remarque-sudba-knigi-zhenshhiny/a-500523 2020-09-25T07:20:41.046Z weekly 0.5 https://www.dw.com/ru/jablochnoe-vino-v-gessene/a-2106445 2020-08-10T09:27:26.178Z weekly 0.5 https://www.dw.com/ru/9-nojabrja ...](https://tvdownloaddw-a.akamaihd.net/stills/images/vdt_ru/2021/brus210106_001_nordstreabbhd_01v.jpg)
https://www.dw.com/ru/erich-maria-remarque-sudba-knigi-zhenshhiny/a-500523 2020-09-25T07:20:41.046Z weekly 0.5 https://www.dw.com/ru/jablochnoe-vino-v-gessene/a-2106445 2020-08-10T09:27:26.178Z weekly 0.5 https://www.dw.com/ru/9-nojabrja ...
![Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study - The Lancet Haematology Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1d8db9b7-a58b-4935-8829-9e0dedd828d9/gr1_lrg.gif)
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study - The Lancet Haematology
![Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial - The Lancet Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/30a6d37e-41b7-431e-a663-928f72f91adb/gr2_lrg.jpg)
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial - The Lancet
![Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial - The Lancet Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3bbecfcf-4284-4b43-b5c8-392594f6fd6f/gr1.gif)